NPCE logo

NEUROPACE INC

NPCENASDAQ
🏆 #3018 by market capUS Equity
$123.85▲ $2.11 (+1.70%)
Simulated price
🔔
Track NPCE
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.7%
7d▲ 741.4%
14d▲ 771.0%
30d▲ 759.5%
ytd▲ 701.1%
1y▲ 1108.3%
🏦Market Cap
$479M
Small Cap
📈Revenue Growth (YoY)
+25.1%
High Growth
📊Gross Margin
79.6%
High
💵FCF Margin
-11.8%
Thin
⚖️P/S Ratio
4.9x
Fair
Otter Score
68
Fair

Trading Snapshot

Day Range
$122.03 – $125.54
52-Week Range
$9.22 – $19.60
Volume
$3.35B
Avg Volume
$3.26B
Shares Outstanding
34.1M
Next Earnings
Nov 24, 2026

Fundamentals Snapshot

Annual Revenue
$100M
Last Q Revenue
$23M
P/E Ratio
-24.6
P/S Ratio
4.9x
EPS (TTM)
$-0.56
Dividend Yield
0.00%
Dilution (1yr)
+9.4%

Why Investors Own NPCE

  • ✓High-growth profile — revenue up +8.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 47% gross margin and 5% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NPCE logo

NEUROPACE INC

NPCE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$100M▲ +25.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
77.2%▲ +4.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$16M▼ −24.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▼ −37.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
32.7M▲ +9.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$49M▲ +$11M YoY
StockOtter · stockotter.space

About NEUROPACE INC

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$140.57
▲ +13.5% Upside
High Target$176.64
Low Target$104.20
Based on 22 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

NEUROPACE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift NPCE price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

NEUROPACE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.